news Measuring microRNAs in blood may indicate dementia risk 14 October 2021 | By Anna Begley (Drug Target Review) Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
news Mission Therapeutics receives $500k grant for Parkinson’s research 14 October 2021 | By Anna Begley (Drug Target Review) Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
news Scientists uncover answer to colorectal cancer immunotherapy resistance 13 October 2021 | By Anna Begley (Drug Target Review) Boosting dendritic cells prevented immunotherapy resistance in mouse models, suggesting a new approach to colorectal cancer therapies.
news New vaccination approach could target “core” of all coronaviruses 12 October 2021 | By Anna Begley (Drug Target Review) Researchers have used genetically engineered SARS-CoV-2 Spike proteins to boost antibodies against a range of coronaviruses in mice.
news Stem cell therapy repairs injured peripheral nerves in animal models 12 October 2021 | By Anna Begley (Drug Target Review) Gingiva-derived mesenchymal stem cells were used to surgically repair injured peripheral nerves, showing potential for new therapies.
news Mesenchymal stem cells could be the key to bone regeneration 11 October 2021 | By Anna Begley (Drug Target Review) Scientists have identified a subpopulation of mesenchymal stem cells with enhanced bone fracture healing and differentiation abilities.
news Oral COVID-19 vaccine reduces transmission in animal model 11 October 2021 | By Anna Begley (Drug Target Review) A new study has suggested that mucosal vaccines may reduce transmission of airborne viruses such as COVID-19 more than injectable vaccines.
news Pre-clinical trials to test if psychedelic drugs reduce alcohol consumption 8 October 2021 | By Anna Begley (Drug Target Review) Landmark pre-clinical studies to investigate whether psychedelic derivatives can reduce alcohol consumption have been initiated.
news Nanobubbles show promise for delivering anti-inflammation treatments 8 October 2021 | By Anna Begley (Drug Target Review) Nanobubbles known as extracellular vesicles (EVs) were shown to deliver protein drugs in animal models with inflammatory diseases.
news Small molecule RGX-202 prevents metastasis in colorectal cancer 7 October 2021 | By Anna Begley (Drug Target Review) RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
news Chemotherapy drug reverses Alzheimer’s symptoms in mice 7 October 2021 | By Anna Begley (Drug Target Review) Axitinib, a common chemotherapy drug, restored memory and cognitive function in mouse models, representing a potential Alzheimer’s treatment.
news Novel “living medicine” could treat antibiotic-resistant infections 6 October 2021 | By Anna Begley (Drug Target Review) Researchers have created the first “living medicine” to treat antibiotic-resistant bacteria growing on the surfaces of medical implants.
news Experimental vaccine a major breakthrough for rheumatoid arthritis 5 October 2021 | By Anna Begley (Drug Target Review) A protein-based vaccine has proven a promising option to prevent rheumatoid arthritis, improving bone quality in animal models.
news Psilera to collaborate with NIDA on pre-clinical psychedelic studies 5 October 2021 | By Anna Begley (Drug Target Review) Psilera will participate in two studies with the National Institute on Drug Abuse to combat addiction using a novel DMT formulation.
news Statistical model defines how ketamine anaesthesia affects the brain 4 October 2021 | By Anna Begley (Drug Target Review) An MIT study has used the first statistical model to finely characterise how ketamine anaesthesia affects the brain, possibly improving patient outcomes.